Key result
Dapagliflozin is linked to improved health status and postexercise recovery in COPD with diastolic dysfunction.
Why the study?
Left ventricular diastolic dysfunction (LVDD) commonly co-occurs with COPD and can adversely affect functionality, quality of life, and survival, but the impact of treating LVDD with dapagliflozin was unclear.
Does add-on dapagliflozin improve postexercise recovery response and health status in patients with stable COPD and LVDD?
Observational (n=35)
Open-label
Does add-on dapagliflozin improve postexercise recovery response and health status in patients with stable COPD and LVDD?
In patients with stable COPD and left ventricular diastolic dysfunction, add-on dapagliflozin significantly improved health status and postexercise recovery response.
Answers are grounded in this paper and cite their sources.
May support add-on dapagliflozin for exercise recovery in COPD with LVDD; hypothesis-generating and requires randomized confirmation before practice change.
Background: Left ventricular diastolic dysfunction (LVDD), a common co-event of chronic obstructive pulmonary disease (COPD), can adversely influence functionality, quality of life (QoL), and survival prospects.Objective: To see the impact of treatment of LVDD with the sodium-glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin in a prospective trial.Materials and methods: Serial consenting patients with stable COPD underwent Doppler echocardiography on clinical or radiological suspicion of LVDD or pulmonary hypertension (PH).The subjects with LVDD were treated with add-on dapagliflozin in an open, prospective, real-world observation.The follow-up (FU) records of the first 35 patients were included for statistical analysis.The treatment effects were measured in terms of changes in postexercise recovery response [two-chair test (2CT)] and health status [COPD assessment test (CAT) score].Results: We included 35 patients of COPD [mean age: 67.66 ± 9.28 years, mean body mass index (BMI): 24.64 ± 3.97] with male predominance: 30:5.Their mean post-bronchodilator (BD) absolute forced expiratory volume in the first 1 second (FEV1)/forced vital capacity (FVC) and mean post-BD percentage predicted FEV1 were 0.50 ± 0.11 and 44.37 ± 15.72, respectively, with hypertension being the commonest comorbidity (30%) followed by diabetes and ischemic heart disease.On echocardiography, they displayed the mean value of pulmonary artery pressure (PAP) (systolic) as 45.43 ± 6.57, E/e' as 13.60 ± 2.52, left atrial volume index as 27.88 ± 8.54 mL/m 2 of body surface area, and tricuspid regurgitation (TR)-jet velocity as 3.04 ± 0.24.On a mean FU of 104.7 ± 70.96 days, they showed statistically significant improvement in postexercise minimum SpO 2 (p = 0.043) and desatmax (p = 0.020) of the 2CT; the CAT score also improved significantly (14.35 ± 3.00-8.93± 4.09; p < 0.0001).Repeat echocardiography, possible in nine patients, showed an improving trend in all parameters.All the patients tolerated dapagliflozin well.Conclusion: Dapagliflozin, an SGLT-2 inhibitor, improves health status and the postexercise recovery response significantly with LVDD in COPD.
No takes yet. Share an insight, caveat, or question.
Bhattacharyya et al. (2026) conducted an observational in Chronic obstructive pulmonary disease with left ventricular diastolic dysfunction (n=35). Dapagliflozin was evaluated on Changes in postexercise recovery response (two-chair test) and health status (COPD assessment test score) (p=<0.0001). Dapagliflozin improved health status and postexercise recovery response in patients with COPD and left ventricular diastolic dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: